e-Therapeutics plc Director/PDMR Shareholding (4609T)
03 July 2018 - 11:08PM
UK Regulatory
TIDMETX
RNS Number : 4609T
e-Therapeutics plc
03 July 2018
E-THERAPEUTICS PLC
("e-therapeutics" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY
PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND ISSUE OF EQUITY
Oxford, UK, 3 July 2018 - e-Therapeutics plc (AIM: ETX), the
drug discovery company, announces that on 2 July 2018 Professor
Trevor Jones (Non-Executive Director) subscribed for a total of
74,526 new ordinary shares of 0.1p each in the Company (the "New
Ordinary Shares") at a price of 7.38 pence per share. The
subscription monies paid for the New Ordinary Shares represent 50%
of Professor Jones' Non-Executive Director fees net of tax paid
during the period from 1 January 2018 to 30 June 2018 in accordance
with the agreement entered into with Professor Jones, previously
announced on 5 October 2016, by which Professor Jones agreed, with
effect from 1 October 2016, to invest 50% of his annual
Non-Executive Director fees net of tax in new e-therapeutics'
ordinary shares. Such new shares are issued to Professor Jones on
the first business day after 31 December and 30 June in each year.
The subscription price to be paid is the average of the closing
mid-market price for the five business days prior to the date of
issue.
Following Admission, Professor Jones will be interested in a
total of 396,247 ordinary shares of 0.1p in the Company,
representing approximately 0.15% of the Company's issued share
capital.
Application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur on 10 July 2018. The New Ordinary Shares will
rank pari passu in all respects with the Company's existing
ordinary shares in issue.
Following Admission, the total number of ordinary shares in the
Company with voting rights in issue will be 268,605,392. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ------------------------------------------------------------
a) Name Trevor Jones
--- ------------------------ ----------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Non-Executive Director
--- ------------------------ ----------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ ----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ------------------------------------------------------------
a) Name e-therapeutics plc
--- ------------------------ ----------------------------------
b) LEI 21380049RHSSJXWKYT18
--- ------------------------ ----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- ------------------------------------------------------------
a) Description of Ordinary Shares of 0.1 pence
the financial
instrument, type ISIN: GB00B2823H99
of instrument
Identification
code
--- ------------------------ ----------------------------------
b) Nature of the Purchase of shares
transaction
--- ------------------------ ----------------------------------
c) Price(s) and 74,526 ordinary shares at a price
volume(s) of 7.38 pence per share
--- ------------------------ ----------------------------------
d) Aggregated information 74,526 ordinary shares
- Aggregated 7.38 pence per share
volume Aggregated value: GBP5,500.02
- Price
--- ------------------------ ----------------------------------
e) Date of the transaction 2 July 2018
--- ------------------------ ----------------------------------
f) Place of the Outside a trading venue
transaction
--- ------------------------ ----------------------------------
For further information, please contact:
E-Therapeutics plc Tel: +44 (0) 1993 883
Ray Barlow, Chief Executive 125
Officer www.etherapeutics.co.uk
Steve Medlicott, Finance
Director
Numis Securities Limited Tel: +44 (0) 207 260
Michael Meade/Freddie Barnfield 1000
(Corporate Finance) www.numis.com
James Black (Corporate Broking)
FTI Consulting Tel: +44 (0) 203 727
Simon Conway/Brett Pollard 1000
Email: etherapeutics@fticonsulting.com
About e-therapeutics
We are an Oxford, UK-based company with a unique and powerful
computer-based drug discovery platform and a specialised approach
to network biology.
Our novel network-driven methodology allows us to discover new
and better drugs in a more efficient and effective way.
We use our highly productive drug Discovery Engine to develop
our own IP-protected, preclinical drug discovery programmes which
will be of interest to partners looking to acquire or in-license
novel and differentiated assets. We are currently developing two
programmes in immuno-oncology and have a number of partner-ready
projects in areas such as fibrosis and tumour microenvironment.
Because of our novel network-driven drug discovery ("NDD")
approach, we believe there is potential to enter into several
different types of collaborative partnerships with biotech, pharma
and other technology companies to create sustainable mutual
value.
About Network-Driven Drug Discovery ("NDD")
e-Therapeutics' proprietary NDD platform comprises a suite of
powerful computational tools to augment and interrogate the vast
amount of biological information currently available in both public
and private databases.
Our NDD platform is founded on sophisticated network science and
employs techniques such as machine learning, artificial
intelligence and state-of-the-art data analysis tools. Using our
biological expertise, we can create and analyse network models of
disease to identify likely proteins that could effectively be
disrupted to treat the disease.
We believe that our network-driven approach more realistically
reflects the true complexity of disease, with its multiple and
often interconnected cellular pathways. By modelling and analysing
disease networks and considering the pattern of connections between
proteins, and not just single pathways, we more efficiently select
the very best drug-like compounds for screening and for subsequent
medicinal chemistry and pre-clinical testing. With our novel
methodology, significant numbers of active molecules can be
identified and tested quickly. Our approach is highly productive
and consistently generates hits that have been progressed into
potent, selective and novel drug molecules.
Our overall aim is to discover more efficacious drugs more
effectively. By using more biologically realistic, cell and
tissue-based assays we can choose and design compounds that are
more likely to translate into better, more clinically efficacious
drugs.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLLFIVDRIVIIT
(END) Dow Jones Newswires
July 03, 2018 09:08 ET (13:08 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024